Advancing the frontier of psychedelic science
Groundbreaking research identifies distinct neural circuits for anxiety reduction versus perceptual effects, potentially enabling therapeutic benefits without intense hallucinations.
Read Full Article →Major institutions launch trials for opioid addiction, Alzheimer's, PTSD, anorexia nervosa, Parkinson's, chronic pain, and post-treatment Lyme disease syndrome.
Read Full Article →New insights into how psychedelics promote structural, functional, and molecular neuroplasticity, with effects persisting weeks after a single dose.
Read Full Article →Phase 2b trial demonstrates significant depression score reductions and high remission rates with tolerable side effects in TRD patients.
Read Full Article →DMT-related compound in Phase 2 trials shows high remission rates for major depressive disorder, attracting major pharmaceutical investment.
Read Full Article →Delix Therapeutics develops rapidly-acting antidepressant that promotes neuroplasticity without hallucinogenic properties in preclinical models.
Read Full Article →Single psilocybin session produces years-long improvements in depression and anxiety for cancer patients, with many requiring no further treatment.
Read Full Article →Major pharmaceutical deals signal industry confidence while regulatory concerns about data and ethics continue to shape the approval landscape.
Read Full Article →Subscribe to receive the latest findings and breakthroughs in psychedelic science